NCT07342062已完成1 期
An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 in Healthy Subjects at Fed State
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- AUCt
研究概览
简要总结
This clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 at fed state.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers
- •BMI between 18 and 30 kg/m2
- •Body weight: Male ≥ 50kg, Female ≥ 45kg
- •Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study
排除标准
- •Subjects with clinically significant medical history
- •Subjects with history of drug abuse or addicted
- •Subjects with allergy or drug hypersensitivity
研究组 & 干预措施
Sequence A
Active Comparator
cross-over
干预措施: DA-1229_01-R (Drug)
Sequence B
Active Comparator
cross-over
干预措施: DA-1229_01-R (Drug)
Sequence B
Active Comparator
cross-over
干预措施: DA-1229_01 (Drug)
Sequence A
Active Comparator
cross-over
干预措施: DA-1229_01 (Drug)
结局指标
主要结局
AUCt
时间窗: pre-dose~24 hours post-dose
Area Under the Curve
Cmax
时间窗: pre-dose~24 hours post-dose
Maximum Plasma Concentration
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting StateNCT07297940Dong-A ST Co., Ltd.40
招募中
1 期
Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.NCT07267221Daewoong Pharmaceutical Co. LTD.36
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy VolunteersType 2 DiabetesNCT07304700Chong Kun Dang Pharmaceutical30
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy VolunteersType 2 DiabetesNCT07304726Chong Kun Dang Pharmaceutical30
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy VolunteersType 2 DiabetesNCT07304687Chong Kun Dang Pharmaceutical31